European Journal of Medicinal Chemistry xxx (xxxx) xxx



Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry



journal homepage: http://www.elsevier.com/locate/ejmech

Research paper

Benzo[d]thiazol-2(3H)-ones as new potent selective CB₂ agonists with anti-inflammatory properties

Natascha Leleu-Chavain ^{a, 1}, Davy Baudelet ^{a, 1}, Valéria Moas Heloire ^c, Diana Escalante Rocha ^a, Nicolas Renault ^a, Amélie Barczyk ^a, Madjid Djouina ^b, Mathilde Body-Malapel ^b, Pascal Carato ^{d, e, **}, Régis Millet ^{a, *}

^a Univ. Lille, Inserm, U995 - LIRIC - Lille Inflammation Research International Center, ICPAL, 3 rue du Professeur Laguesse, BP-83, F-59006, Lille, France ^b Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, Faculty of Medecine, Place Verdun, F-59045, Lille Cedex, France

^c Université de Lille, EA 4481, Laboratoire de Chimie Thérapeutique, 3 rue du Professeur Laguesse, BP-83, F-59006, Lille, France

^d Université de Poitiers, UFR de Médecine et de Pharmacie, 6 rue de la Milétrie Bât D1 - TSA 5115, 86073, Poitiers, France

^e CIC INSERM 1402, UFR Médecine Pharmacie, Poitiers, France

ARTICLE INFO

Article history: Received 17 September 2018 Received in revised form 13 November 2018 Accepted 3 December 2018 Available online xxx

Keywords: CB₂ agonist Inflammation Colon inflammatory

ABSTRACT

The high distribution of CB₂ receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: selective CB₂ agonists are able to modulate inflammation without triggering psychotropic effects. In this work, we report a new series of selective CB₂ agonists based on a benzo[*d*]thiazol-2(3*H*)-one scaffold. This drug design project led to the discovery of compound **9**, as a very potent CB₂ agonist ($K_i = 13.5 \text{ nM}$) with a good selectivity *versus* CB₁. This compound showed no cytotoxicity, acceptable ADME-Tox parameters and demonstrates the ability to counteract colon inflammatory process *in vivo*.

© 2018 Elsevier Masson SAS. All rights reserved.

1. Introduction

Isolated in 1964 by Yechiel Gaoni and Raphael Mechoulam [1], Δ^9 -Tetrahydrocannabinol (Δ^9 -THC) is the main psychoactive substance found in the cannabis plant (Fig. 1) [2]. Δ^9 -THC displays a wide range of physiological effects including analgesic, antiinflammatory and immunosuppressive activities [3,4] but its clinical use is limited because of its abuse potential and psychomimetic side effects. Δ^9 -THC acts mainly on the endocannabinoid system, which modulates various physiological functions: motor function, memory, motivation, energy, pain and emotion [5]. More specifically, most of the Δ^9 -THC properties are mediated by two G-protein coupled receptors, called cannabinoid receptors, CB₁ and CB₂ [6].

Since the last decade, the interest for the therapeutic use of

https://doi.org/10.1016/j.ejmech.2018.12.008 0223-5234/© 2018 Elsevier Masson SAS. All rights reserved. cannabis was reconsidered leading to many research works on the subject [7-11]. Natural and synthetic cannabinoids have beneficial effects on several diseases including asthma, glaucoma and Alzheimer's disease [12]. They exert also antiemetic, antiinflammatory and analgesic effects [4,13]. Unfortunately, these therapeutic effects are associated with side effects linked to the CB₁ receptor [14], like memory alteration, dysphoria and sedation [15]. Indeed, CB₁ receptors are mostly located in the brain and thus are responsible for central effects of cannabinoids [16]. However, CB₂ receptors are mainly expressed in peripheral immune cells [17] and their activation mediates immune responses and explains their therapeutic potential [13].

To prevent these adverse effects, several strategies can be envisaged to target CB_2 selectively: the development of (1) selective CB_2 agonists that will not activate CB_1 receptors; (2) endocannabinoid degradation enzyme inhibitors, like FAAH inhibitors, that will enhance the level of endocannabinoids; (3) ligands that do not pass the blood-brain barrier; or (4) ligand vectors like nanoparticles to specifically reach the target.

Recently, a great deal of research have been undertaken in the development of selective CB_2 agonists. Various molecules have

^{*} Corresponding author.

^{**} Corresponding author. Université de Poitiers, UFR de Médecine et de Pharma-

cie, 6 rue de la Milétrie Bât D1 - TSA 5115, 86073, Poitiers, France.

E-mail addresses: pascal.carato@univ-poitiers.fr (P. Carato), regis.millet@univ-lille2.fr (R. Millet).

¹ These authors contributed equally to this work.

2

ARTICLE IN PRESS

N. Leleu-Chavain et al. / European Journal of Medicinal Chemistry xxx (xxxx) xxx




Fig. 1. Δ^9 -Tetrahydrocannabinol (Δ^9 -THC) and selected CB₂ agonists.

been synthesized with very good biological properties. These selective CB₂ agonists are structurally very different like heterocyclic ylidenes (compound 1) [18], 4-oxo-1,4-dihydropyridines (**ALICB515**) [19], isoxazoles (**ALIAE809**) [20], benzoimidazoles (**RQ-00202730**) [21], imidazopyridines (compound 2) [22] or purines (compound 3) [23], for example (Fig. 1). Despite the structural diversity of these compounds, they are often characterized by lipophilic properties due to the presence of aromatic heterocycles, bulky alkyl or aryl substituents. However compounds (compound 4) with low LogP value are recently reported [24]. Some selective CB₂ agonists are currently in clinical trials for the treatment of pain, osteoartitis, atopic dermatitis or systemic scleroderma (Fig. 2) [25].

Benzothiazolone and benzoxazolone have been qualified as "privileged scaffolds" in drug design [26]. These frameworks have found broad therapeutic applications from analgesic and antiinflammatory compounds [27–29] to Alzheimer's disease treatment [30] and anticonvulsant compounds [31]. Nevertheless, only few benzothiazolone derivatives have been reported with antiinflammatory properties. Among these molecules, we can point tiaramide [32,33] and S-14080 [34] (Fig. 3).

With the ambition to develop selective CB₂ agonists for the treatment of inflammatory bowel diseases, we investigated the synthesis and structure-activity relationship of new benzazolones. Then, from our previous work on selective CB_2 agonists [35–37], we have identified some pharmacophoric elements to be essential for activity and selectivity: (a) a long aliphatic chain (R¹), which extends toward a hydrophobic region of the receptor, is optimal for a good CB₂ affinity; (b) a hydrogen bond acceptor (X) able to interact with Ser285 plays an important role in the molecular recognition and (c) a bulky hydrophobic group (R_2) fitting with a second hydrophobic pocket, is favorable for a good CB₂ affinity and selectivity. Following this combination of hydrogen bond and hydrophobic interactions, we assumed that the benzo[d]thiazol-2(3H)-one scaffold, suitably substituted with an aliphatic chain and a bulky hydrophobic group, could provide the starting point for the identification of new selective CB₂ agonists.

22 new compounds (5-26) were synthesized and tested for

their CB₂ binding affinity (Fig. 4). The CB₂ selectivity compared to CB₁, functionality and cytotoxicity were evaluated for the most affine molecules. Finally, ADME properties of our best selective CB₂ agonist (compound **9**) were determinated and *in vivo* anti-inflammatory activity was evaluated on a dextran sulfate sodium (DSS)-induced experimental colitis assay.

2. Results and discussion


2.1. Chemistry

As described previously, compounds **5–19** were synthesized *via* a Stille coupling from the tributylstannyl intermediates **37–43**, which were obtained after *N*-alkylation at the *N*3-position of the corresponding 6-bromobenzo[*d*]thiazol-2(3*H*)-ones **30–34**, and 5-bromobenzo[*d*]thiazol-2(3*H*)-one **35** and 6-bromobenzo[*d*]xazol-2(3*H*)-one **36** (Scheme 1) [38]. It has already been demonstrated that it is necessary to *N*-alkylate at the *N*3-position before coupling because the NH acid group of the benzo[*d*]thiazol-2(3*H*)-one interacts in the Stille reaction [39]. Indeed, Stille reaction is sensitive to acid media or acid groups.

6-Bromobenzo[*d*]thiazol-2(3*H*)-one **27** [40], 5-bromobenzo[*d*] thiazol-2(3H)-one **28** [41] and 6-bromobenzo[d]xazol-2(3H)-one **29** [40] were prepared according to already described procedures. Compounds 30-36 were obtained by nucleophilic substitution of corresponding haloalcane by the heterocyclic nitrogen atom of the corresponding benzo[d]thiazol-2(3H)-one or benzo[d]xazol-2(3H)one. This reaction was performed in DMF at 80 °C in presence of an excess of Cs₂CO₃. The desired compounds 30-36 were obtained with moderate to good yields (38-98%). Then, the tin intermediates 37-43 were prepared by reaction of the previous alkylated compounds (30-36) with Bu₃Sn)₂ in dry toluene at 80 °C in the presence of $Pd(PPh_3)_4$ with low to good yields (9–79%). The obtained stannyl intermediates 37–43 were then refluxed in dry toluene with the corresponding acyl chloride in the presence of PdCl₂(PPh₃)₂. The final compounds 5–19 were obtained with low to good yields (6-89%).


N. Leleu-Chavain et al. / European Journal of Medicinal Chemistry xxx (xxxx) xxx

Compounds	Х	R ¹	R ²	Position of (C=O)R ²
5	S	<i>n</i> -pentyl	cyclohexyl	6- position
6	S	<i>n</i> -pentyl	phenyl	6- position
7	S	<i>n</i> -pentyl	2,2,3,3-tetramethyl cyclopropyl	6- position
8	S	<i>n</i> -pentyl	cyclopentyl	6- position
9	S	<i>n</i> -pentyl	1-adamantyl	6- position
10	S	<i>i</i> -propyl	1-adamantyl	6- position
11	S	<i>n</i> -butyl	1-adamantyl	6- position
12	S	n-hexyl	1-adamantyl	6- position
13	S	2-dimethyl aminopropyl	1-adamantyl	6- position
14	0	<i>n</i> -pentyl	1-adamantyl	6- position
15	0	<i>n</i> -pentyl	cyclohexyl	6- position
16	0	<i>n</i> -pentyl	2,2,3,3-tetramethyl cyclopropyl	6- position
17	S	<i>n</i> -pentyl	1-adamantyl	5- position
18	S	<i>n</i> -pentyl	cyclohexyl	5- position
19	S	<i>n</i> -pentyl	2,2,3,3-tetramethyl cyclopropyl	5- position




GW842166 osteoartitis pain Phase 2 completed


 $GlaxoSmithKline \\ hCB_2 EC_{50} = 342.8 \text{ nM} \\ hCB_1 EC_{50} > 1000 \text{ nM}$




GRC10693 (Tedalinab) neuropathic pain, osteoartritis Phase 1 completed *Glenmark Pharmaceuticals* hCB₂ Ki = 11.8 nM hCB₁ Ki = 985.2 nM



LY2828360 knee pain, osteoartritis Phase 2 *Eli Lilli* hCB₂ Ki = 40.0 nM hCB₁ Ki > 1000 nM



AZD-1940 pain Phase 1 *AstraZeneca* hCB₂ Ki = 0.87 nM hCB₁ Ki = 11.7 nM



S-777469 atopic dermatitis Phase 2 Shionogi & Co. $hCB_2 Ki = 36 nM$ $hCB_1 Ki = 4607 nM$

Fig. 2. Selected most important CB₂ agonists in clinical development.







Fig. 3. Anti-inflammatory benzothiazolone derivatives.




R¹: i-propyl, n-butyl, n-pentyl, n-hexyl, 2-dimethylaminopropyl





X: CO, CH_2 , CHOH, $CHOCH_3$, CNOH, CNOCH₃, CONH, NHCO

Fig. 4. Design and structural modifications of benzazolone derivatives 5-26.



Scheme 1. Synthesis of compounds 5–19.


Reagents and conditions: (a): $C_{s_2}CO_3$, R^1Br , DMF, $80 \,^{\circ}C$; (b): $(SnBu_3)_2$, $Pd(PPh_3)_4$, toluene, $80 \,^{\circ}C$; (c): $PdCl_2(PPh_3)_2$, R^2COCl , toluene, reflux.

Modification of the ketone function of compound **9** was carried out either starting from compound **9** (Scheme 2) or from benzo[d] thiazol-2(3H)-one (Schemes 3 and 4).

Starting from compound **9**, compound **20** was obtained by total reduction of the ketone function using Et_3SiH in TFA with a yield of 16%. Compound **21** was obtained by partial reduction of the ketone function of compound **9** using NaBH₄ in methanol with a yield of 26% [42]. The hydroxyl function of compound **21** was then methylated in THF in presence of NaH and methyl iodide to give compound **22** with a yield of 39%. The hydroxylimine **23** and methoxyimine **24** were synthesized by reaction of compound **9** with hydroxylamine or methylamine hydrochlorides respectively, in refluxing methanol in the presence of pyridine. The desired compounds **23** and **24** were obtained with a yield of 25% and 15%, respectively.


Carboxamide **25** was synthesized starting from benzo[d]thiazol-2(3*H*)-one (Scheme 3).

First, the benzothiazole was acetylated regioselectively at the



Scheme 2. Synthesis of compounds 20-24.

Reagents and conditions: (a): TFA, Et₃SiH, rt; (b): NaBH₄, MeOH, rt; (c) XO-NH $_3^+$ Cl⁻, pyridine, MeOH, reflux; (d): NaH, THF, rt; (e) CH₃I.



Scheme 3. Synthesis of compound 25.

Reagents and conditions: (a): acetylchloride, AlCl₃, DMF, 70 °C; (b): NaOCl, NaOH, H₂O, reflux; (c): HCl; (d): 1-adamantaneammonium chloride, HOBt, HBTU, DIEA, DMF; (e): $C_5H_{11}Br$, K_2CO_3 , DMF, 80 °C.

C6-position by a Friedel-Crafts reaction in presence of aluminium chloride (AlCl₃) in DMF at 70 °C to give acetylbenzo[*d*]thiazol-2(3*H*)-one **44** with a yield of 48% [38]. The acetyl group was then oxidized through an haloform reaction in a NaOH solution in presence of NaOCl at reflux [43]. The carboxylic acid **45** was obtained with a yield of 50%. The resulted carboxylic acid **45** was coupled to 1-adamantylamine in presence of HBTU, HOBt and DIEA in DMF at room temperature to give carboxamide **46** with 14% yield. Finally, the *N*3-position was alkylated using 1-bromopentane in DMF in presence of K₂CO₃ at 80 °C to give the desired compound **25** with 22%.

Carboxamide **26** was synthesized in 4 steps starting from benzo [*d*]thiazol-2(3*H*)-one (Scheme 4).

Nitration of the benzothiazole with nitric acid in acetic anhydride at 0 °C gave mainly 6-nitrobenzo[*d*]thiazol-2(3*H*)-one **47** with 60% yield [44]. Two side products were also obtained: nitration at the position 4 and bisnitration at positions 4 and 6. After *N*alkylation by 1-bromopentane at the *N*3-position in DMF in presence of an excess of K₂CO₃ at 80 °C (compound **48**, yield 69%), the nitro function was reduced by catalytic hydrogenation (H₂, Pd/C, MeOH) to afford to amine **49** with a yield of 57%. Finally, the benzo [*d*]thiazol-2(3*H*)-one **26** was obtained by nucleophilic substitution. This Schotten-Baumann reaction was carried out in a two-phase medium (water/ethylacetate) in presence of adamantane-1carbonyl chloride and K₂CO₃ to give the final compound **26** with a yield of 69%.

2.2. In vitro binding assays

We first synthesized a series of 5 compounds (**5–19**, Table 1) characterized by different substituents at positions 3, 5, 6 of the benzothiazolone or benzoxazolone scaffold.

The affinities of the new synthesized compounds together with WIN-55,212-2 and JWH-133, reference compounds, for the human CB_2 receptor (hCB_2) were determined by a competitive radioligand displacement assay using [³H]-CP55,940 as radioligand [45]. Membranes from Chinese hamster ovary (CHO) cells expressing hCB_2 were used in these experiments. All compounds were first screened at a concentration of 10 µM for their affinity toward the cannabinoid receptor. Inhibition constant (K_i) values were determined for compounds exhibiting a specific displacement superior to 60% for hCB₂. As shown in Table 1, among these 9 molecules, 7 displayed good to moderate inhibition constants. No CB₂ affinity was observed for compounds 6 and 7 with a phenyl or a 2,2,3,3tetramethylcyclopropyl group at position 6 and compound 8 with a cyclopentyl group at the same position showed only moderate CB₂ affinity. These observations suggest that an adamantyl group or a cyclohexyl group are the best substituents at position 6. Regarding the alkyl chains introduced on the heterocyclic nitrogen atom at position 3, the optimal length appears to be chains varying from 4 to 6 carbons. When a shorter (isopropyl, compound **11**) or a dimethylamino functionalized chain (compound 14) are introduced, a decrease of CB₂ affinity is observed. From these 9 molecules, compound 9 with a *n*-pentyl chain on the heterocyclic nitrogen and an adamantly group at position 6 showed the best affinity for CB₂.


Using this compound **9** as a starting hit, a first phase of structural analysis has been achieved by preserving both substituents and varying (1) the position of the bulky group R^2 from position 6 to position 5 (compounds **14–16**, Tables 1) and (2) the nature of the central scaffold by replacement of the sulfur by an oxygen (compounds **17–19**, Table 1). As show, the shift of the bulky group to the 5 position, as well as the substitution of the benzothiazolone by a benzoxazolone scaffold result in a deep decrease or even a loss of CB₂ affinity.

Please cite this article as: N. Leleu-Chavain et al., Benzo[*d*]thiazol-2(3*H*)-ones as new potent selective CB₂ agonists with anti-inflammatory properties, European Journal of Medicinal Chemistry, https://doi.org/10.1016/j.ejmech.2018.12.008

4

DRESS

N. Leleu-Chavain et al. / European Journal of Medicinal Chemistry xxx (xxxx) xxx



Scheme 4. Synthesis of compound 22.

Reagents and conditions: (a): HNO3, (CH3CO)2O, 0°C; (b): C5H11Br, K2CO3, DMF, 80°C; (c): H2, Pd/C, MeOH, rt; (d): adamantylacid chloride, K2CO3, H2O, EtOAc, rt.

Table 1

 hCB_2 and hCB_1 affinities^a and selectivity index (SI) of compounds **5–19**.

Compd	Х	\mathbb{R}^1	R ²	Position of (C=O)R ²	$hCB_2 K_i (nM)$	$hCB_1 K_i (nM)$	SI
5	S	<i>n</i> -pentyl		6	49.5 ± 14.5	>1000	>20
6	S	<i>n</i> -pentyl	r Q	6	^{>} 1000	N.D. ^b	N.D.
7	S	<i>n</i> -pentyl	, K	6	^{>} 1000	N.D.	N.D.
8	S	<i>n</i> -pentyl	e ^{ge}	6	210 ± 36	>1000	>5
9	S	<i>n</i> -pentyl	est.	6	13.5 ± 1.5	627 ± 230	46
10	S	<i>i</i> -propyl	D.	6	280.5 ± 14.5	>1000	>4
11	S	n-butyl	D.	6	26 ± 7	780 ± 191	30
12	S	n-hexyl	Dys	6	39 ± 6	903 ± 10	23
13	S	2-dimethyl aminopropyl	Dy	6	506 ± 264	N.D.	N.D.
14	S	<i>n</i> -pentyl	Dys	5	525.8 ± 58.6	N.D.	N.D.
15	S	<i>n</i> -pentyl	() dat	5	^{>} 1000	N.D.	N.D.
16	S	<i>n</i> -pentyl	, And	5	^{>} 1000	N.D.	N.D.
17	0	<i>n</i> -pentyl	er Der	6	^{>} 1000	N.D.	N.D.
18	0	<i>n</i> -pentyl		6	* 1000	N.D.	N.D.
19	0	<i>n</i> -pentyl	er.	6	* 1000	N.D.	N.D.
WIN-55,212–2 JWH-133					1.57 ± 0.21 8 ± 1	19±11 >1000	12 >125

а The K_i values were obtained from nonlinear analysis of competition curves using [³H]-CP-55,940 as radioligand for hCB₂ and hCB₁ cannabinoid receptors and are expressed as mean \pm SEM of at least four experiments performed in duplicate. ^b Not determined.



Table 2

 hCB_2 and hCB_1 affinities^a and selectivity index (SI) of compounds **20–26**.

Compd	Х	$hCB_2 K_i (nM)$	$hCB_1 K_i (nM)$	SI
20 21	CH ₂	144 ± 18 272 ± 4	593 ± 217 >1000	4 >4
22	CH3	344 ± 120	>1000	>3
23	s st , t st , ⊨ N. _{OH}	251 ± 134	>1000	>4
24	^{s^tℓ, ⁵²² N_OCH₃}	438 ± 136	N.D. ^b	N.D.
25	N N N N N N N N N N N N N N N N N N N	^{>} 1000	N.D.	N.D.
26	O N N H	^{>} 1000	N.D.	N.D.
WIN-55,212—2 JWH-133	_ _	1.57 ± 0.21 8 ± 1	19±11 >1000	12 >125

^a The K_1 values were obtained from nonlinear analysis of competition curves using [³H]-CP-55,940 as radioligand for hCB_2 and hCB_1 cannabinoid receptors and are expressed as mean \pm SEM of at least four experiments performed in duplicate. ^b Not determined.

In order to validate the role of the ketone between the central heterocycle and the adamantyl group in the binding, this function was removed or substituted by other functions. Seven additional compounds were synthesized to this end (Table 2).

In 4 cases, the replacement of the ketone by an hydroxylmethyl

Table 3

	Functionality and cy	totoxicity on HT2	9 cells ^b of identified	l selective CB ₂ li	gands 5, 9 and 11–12
--	----------------------	-------------------	------------------------------------	--------------------------------	----------------------

(compound **21**), a methoxy (compound **22**), an hydroxyiminomethyl (compound **23**) or a methoxyiminomethyl (compound **24**) group strongly decreased CB₂ affinity. When the ketone is replaced with amides (compounds **25–26**), the compounds lost totally their CB₂ affinity. Surprisingly, the suppression of the ketone function (compound **20**), that increase the flexibility of the molecule, showed only a slight diminution in CB₂ affinity.

In order to evaluate the selectivity of our new CB₂ ligands, their affinity toward hCB₁ receptor was determinated. Only molecules showing a good to moderate affinity for hCB₂ ($K_i < 400$ nM) were tested with the same competitive radioligand displacement assay using the same radioligand. All CB₂ ligands showed no significant affinity for CB₁ ($K_i > 590$ nM) (Tables 1 and 2).

2.3. Functionality analysis

Function activity of most selective benzo[*d*]thiazol-2(3*H*)-ones (SI > 20) with the best hCB₂ affinities ($K_i < 50$ nM) was investigated by using a guanosine-5'-O-(3-[³⁵S]-GTP γ S) binding assay and hCB₂-CHO cells membranes, as previously described [42]. This assay consists in a functional measurement of the interaction between the receptor and the G-protein, which constitutes the first step of the G-protein coupled receptor activation. In this assay, antagonists do not affect [³⁵S]-GTP γ S interaction whereas agonists and inverse agonists increase or decrease the binding, respectively. The functional activity of the reference cannabinoid agonist, WIN-55,212–2 (CB₁ and CB₂ agonist), was also determined. Maximum efficacy (E_{max}) and half-maximal effective concentration (EC₅₀) values of the new synthesized compounds and reference are summarized in Table 3. All tested compounds showed a good to moderate efficacy and have been identified as hCB₂ agonists ($E_{max} > 100\%$) (Table 3).

2.4. In silico 3D analysis

Interaction of the most relevant compounds with CB_2 target has been simulated docking them into a agonist-bound state of a CB_2 receptor model. The ligand binding modes which will be illustrated and discussed are based onto their statistical representation among the docking solutions provided for each molecule. Docking of

Compd		$[^{35}S]$ -GTP γ S(hCB ₂)		Cytotoxicity (HT29) at $10 \mu M$	
	Structure	EC ₅₀ (nM)	E_{\max} (%)		
5		41.5 ± 3.6	178 ± 15	67%	
9	۔ لر	41.9 ± 5.2	157 ± 3	0%	
11	5	150 ± 18	152 ± 7	0%	
12	~	32.8 ± 8.7	169 ± 8	0%	
	Dy Cost				
WIN-55,212-2	_	11.5 ± 3.4	181 ± 12	-	

^bThe cytotoxicity values are expressed as the percentage of cellular proliferation inhibition of at least four experiments performed in duplicate.

reference CB₂ agonists like HU-210, JWH-133 and WIN-55,212-2 as well as compound **9** resulted in 100% of poses within 1.5 Å for each compound (Fig. 5). Most of intermolecular interactions are hydrophobic contacts towards two pockets. The first one is extending toward TM2 (Phe91, Phe94, His95) TM3 (Phe106, Ile110, Val113), TM5 (Leu185) and TM7 (Ala282, Ser285) whereas the second one is more buried into the receptor in the vicinity of TM3 (Thr114, Phe117)), TM5 (Leu191, Trp194), and TM6 (Trp258, Met265). As also identified in a previous CB₂ model [46], the only residue able to establish hydrogen bond with ligands, here HU-210 and WIN-55,212, is Ser285. Nevertheless it is not essential to the binding since JWH-133 and compound 9 do not interact with Ser285. Concerning the docking of other molecules, compounds with an adamantyl group fit fairly converging toward a unique binding mode whereas molecules with aromatic or cyclohexyl groups can adopt a lot of poses in the binding site making them not specific. This method of docking seemed to tag molecules with a substitution of alkyl groups in position 5 less specific than in position 6. Nevertheless, this protocol cannot explain the structure-activity relationships according to the size of alkyl chain as well as the critical impact of benzothiazole versus benzoxazole scaffold.

2.5. Cell proliferation assay

Cytotoxicity of our 11 selective CB_2 agonists was determined at 10 μ M using a cell proliferation assay on human colorectal adenocarcinoma cells HT29. This test is based on a colorimetric method, which measures the activity of cellular enzymes that reduce the tetrazolium dye (MTS, uncolored) to its insoluble formazan giving a purple color. This assay measures cellular metabolic activity *via* NADPH-dependent cellular oxidoreductase enzymes and reflects, under defined conditions, the number of viable cells. The majority of our selective CB₂ agonists showed no cyctotoxicity. Only compound **5** showed a cytotoxicity on HT29 cells at 10 μ M (Table 3).

2.6. Anti-inflammatory effects of 9 in a murin model of acute colitis

Considering its good affinity for hCB₂, selectivity versus hCB₁ and agonist property, compound 9 has been selected for the in vivo study. Specific Pathogen Free male C57/Bl6 mice received 2.5% dextran sodium sulfate (DSS) in drinking water during 9 days. Concomitantly, they were dosed intraperitoneally with compound **9** in hydroxypropyl β cyclodextrine (150 mM) at the dosage of 10 mg/kg body weight. Control mice were injected with hydroxypropyl β cyclodextrine only. Mice developed progressive weight loss, the first clinical sign of colitis development, starting day 4 after DSS administration initiation (Fig. 6A). At day 9, whereas control mice presented a $79.5 \pm 1.8\%$ of body weight variation from their initial body weight, the body weight change in mice treated with compound **9** was significantly improved $(85.9 \pm 2.0\%, p = 0.04)$ respectively, Fig. 6B). Another disease indicator measured was colon length/size ratio because DSS typically results in shortening and thickening of the colon, therefore to an increased colon weight/size ratio. We showed that mice treated with 9 had significantly lower colon weight/size ratio (0.044 ± 0.0024) , p = 0.004 respectively) compared to control mice (0.050 ± 0.0014) , Fig. 6C). We then




Fig. 5. Docking of HU-210 (A), WIN-55,212 (B), JWH-133 (C) and compound 9 (D) into an agonist-bound model of CB2 receptor.




Fig. 6. Effects of **9** daily treatment (10 mg/kg, IP) on body weight (A and B), colon weight/size ratio (C) and MPO activity (D) during DSS-induced acute colitis. Quantification by real-time PCR of colon iNos (E) and Sod2 (F) mRNA levels in mice with DDS-induced colitis treated with vehicle and **9**. Values are expressed as a mean \pm SEM, n = 10.*p < 0.01, ***p < 0.001.

measured colon myeloperoxidase (MPO) activity, reflecting polynuclear neutrophil infiltration (Fig. 6D). A 43% inhibition of MPO activity was quantified in colons of mice treated with **9** compared to control mice $(1.3 \pm 0.20 \text{ vs } 2.2 \pm 0.31, \text{ p} = 0.04)$. These data concordantly bring evidence that intraperitoneal administration of **9** inhibit the development of DSS-induced colitis.

To go further, we quantified by real-time PCR the colonic mRNA levels of several mediators of inflammation. Administration of **9** resulted in a significant reduction of 2 key enzymes of oxidative stress, *iNos* $(0.4 \pm 0.1 \ vs \ 1.0 \pm 0.2$, p = 0.02, Fig. 6E) and *Sod2* $(1.2 \pm 0.4 \ vs \ 2.0 \pm 0.4$, p = 0.02, Fig. 6F). Taken together, these different parameters demonstrate the ability of compound **9** to counteract colon inflammatory process.


2.7. In vitro ADME-Tox parameters

In vitro ADME-Tox properties have been performed for compound **9**. ADME profiling comprises solubility, plasma protein binding, Caco-2 permeability and human microsomal stability (Table 4).

Despite compound **9** exhibited high (lipophilicity (CLogP = 5.6 and CLogP>5), that often contributes to high metabolic turnover and correlates with its ability to passively cross the blood–brain barrier (BBB), compound **9** exhibited high *in vitro* metabolic stability with a half-life around 50 min and 43% of compound remaining after 60 min of incubation with human liver microsomes. Caco-2 permeability was moderate and the efflux ratio of 0.7 indicates that compound **9** is not a substrate of an efflux pump. Intestinal and gastric solubility was high (107 and 183 μ M, respectively). Nevertheless, no solubility at pH 7.4 was observed. It was found that compound **9** binds strongly to plasma proteins, resulting in 10% being in the free form. ADME profile of compound **9** is acceptable but needs to be improved in the future optimization study to consider oral administration.

Table 4

Determination and evaluation of selected physicochemical and *in vitro* ADME-Tox parameters for compound **9**.



Parameters ^c MW (g/mol) CLog P tPSA	383.55 5.6 37.38
In vitro ADME-Tox	
Aqueous solubility (μM) ^d Simulated intestinal fluid PBS, pH 7.4 Simulated gastric fluid	107.3 1.0 183.4
Protein binding (plasma, human) ^e % Protein Bound % Recovery	89% 100%
Caco-2 permeability ^f A-B permeability ($\times 10^{-6}$ cm s ⁻¹) B-A permeability ($\times 10^{-6}$ cm s ⁻¹) Ratio (B-A)/(A-B)	1.8 1.3 0.7
Intrinsic clearance (liver microsomes — human) ^g % compound remaining after 60 min incubation Half-Life (min) Cl _{int} (µLmin ⁻¹ .mg ⁻¹)	43 48 145.6

^cDetermined with ChemBioDraw Ultra 12.0.

^dAssessed by shake-flask method (24 h) at RT.

^eAssessed by equilibrium dialysis (4 h) at 37 °C.

^fCompound **9** was incubated (0 and 60 min) at $37 \degree C$ with Caco-2 cell line (pH 6.5/7.4).

 $^{g}\text{Compound}~\textbf{9}$ was incubated (0 and 60 min) at 37 $^{\circ}\text{C}$ with human liver microsomes (0.1 mg/mL).

3. Conclusion

An original series of selective CB₂ agonists was designed around the benzo[d]thiazol-2(3H)-one scaffold. 22 new compounds have been synthesized, leading to the discovery of a very potent and selective CB₂ agonist (compound **9**, $K_i = 13.5$ nM). Pharmacomodulations were carried out and allowed to evidence (Fig. 7) that the ketone function between the central heterocycle and the bulky aliphatic group plays an important role in the molecular recognition. Position 6 was highlighted to be the optimal position for the hydrophobic group. We have also shown that the replacement of the benzothiazolone by a benzoxazolone resulted in the loss of CB₂ affinity. Compound 9 has shown a strong protective effect in the in vivo DSS-induced colitis mouse model, with an improved body weight, a lower colon weight/size ratio, and a decrease of MPO activity. A reduction of 2 key enzymes of oxidative stress (iNos and *Sod2*) highlight the ability of these compounds to counteract colon inflammatory process. ADME-Tox profile of compound 9 is acceptable but needs to be improved to consider oral administration. Taking together, these results suggest that benzo[d]thiazol-2(3H)-one scaffold could open new perspectives for the development of new CB₂ receptor agonists.

4. Experimental section

4.1. Pharmacology

 hCB_1 and hCB_2 membranes of CHO cells were purchased from Perkin Elmer. Fatty acid free bovine serum albumin (BSA) was purchased from Sigma Chemical Co. (St. Louis, MO). WIN-55,212-2 was purchased from RBI (Natick, MA) and JWH-133 from Tocris (Bristol, UK). [³H]-CP-55,940 (101 C_i/mol) was purchased from NEN Life Science (Zaventem, Belgium). Glass fiber filters were purchased from Whatman (Maidstone, UK), while Aqualuma was from PerkinElmer (Schaesberg, TheNetherlands). $[^{35}S]$ -GTP γ S (1173 C_i/ mmol) was from Amersham (Roosendaal, The Netherlands).

4.2. Binding activities

Stock solutions of the compounds were prepared in DMSO and further diluted (100 times) with the binding buffer to the desired concentration. Final DMSO concentrations in the assay were less than 0.1%. The competitive binding experiments were performed as described earlier [47]. Briefly, [³H]-CP-55,940 (1 nM) as radioligand for the hCB_1 and the hCB_2 cannabinoid receptor was added to 40 µg of membranes resuspended in 0.5 mL (final volume) binding buffer (50 mM Tris-HCl, 3 mM MgCl₂, 1 mM EDTA, 0.5% bovine serum albumine, pH 7.4). After 1 h at 30 °C, the incubation was stopped and the solutions were rapidly filtered through 0.5% PEI pretreated GF/B glass fiber filters on a M-48T Brandell cell harvester and washed twice with 5 mL of ice-cold binding buffer without serum




Fig. 7. Structure-affinity relationships of benzo[d]thiazol-2(3H)-one-based selective CB₂ agonists.

albumin. The radioactivity on the filters was measured using a Pharmacia Wallac 1410 β-counter using 10 mL of Aqualuma, after 10 s shaking and 3 h resting. Assays were performed at least in triplicate. The non specific binding was determined in the presence of 10 uM HU-210.

4.3. $[^{35}S]$ -GTP γS assavs

The binding experiments were performed at 30 °C in tubes containing 40 µg protein in 0.5 mL (final volume) binding buffer (50 mM Tris-HCl, 3 mM MgCl₂, 1 mM EDTA, 100 mM NaCl, 0.1% bovine serum albumin, pH 7.4) supplemented with 20 µM GDP. The assay was initiated by the addition of $[^{35}S]$ -GTP γ S (0.05 nM, final concentration). After 1 h, the incubations were terminated by the addition of 5 mL of ice-cold washing buffer (50 mM Tris-HCl, 3 mM MgCl₂, 1 mM EDTA, 100 mM NaCl). The suspension was immediately filtered through GF/B filters using a 48 well Brandell cell harvester and washed twice with the same ice-cold buffer. The radioactivity on the filters was counted as mentioned above. Assays were performed in triplicate. The non specific binding was measured in the presence of 100 µM Gpp(NH)p. Results were expressed as EC₅₀ (nM) and E_{max} (%). Basal constitutive activity of the receptor has been set at a value of 100%; reported E_{max} values above 100% indicated that the compound behaves as an agonist (either partial or full), values fewer than 100% indicated inverse agonist properties.

4.4. Cell culture and cell proliferation assay

Colon cancer cells (HT29) were grown at 37 °C in a humidified atmosphere containing 5% CO₂ in DMEM + Glutamax-I (Gibco) supplemented with 10% fetal bovine serum, penicillin (100 IU/mL), and streptomycin (100 μ g/mL). In the cell proliferation assay, cells were plated in triplicate on 96-well plates (3000 cells/well) and incubated for 24 h. The cells were then incubated in culture medium that contained a 10 µM concentration of tested compounds, each dissolved in less than 0.1% DMSO. After 72 h, cell growth was estimated by the colorimetric MTS test.

4.5. Animals

Six weeks old C57BL6 male mice were purchased from JANVIER Laboratory (Le Genest St. Isle, France). Animals were maintained in specific pathogen free conditions. All animal experiments were approved by local animal care program (Authorization number 00448.01) and were in accordance with European convention on research animal protection.

4.6. Induction of acute colitis

Acute colitis was induced with 2.5% (w/v) DSS (molecular mass 35-50 kDa, TdB consultancy) dissolved in sterile, distilled water ad libitum for 9 days. The DSS solutions were made fresh every 2 days. Body weight was determined regularly. At day 9, mice were euthanized, colons were weighted and sized then stored for molecular analysis.

4.7. Colon myeloperoxidase activity measurement

MPO activity was measured to monitor the degree of neutrophil infiltration in the colonic lesions in DSS-induced colitis. Colon specimens were homogenized with an Ultra Turrax T8 (Ika-Werke, Staufen, Germany) in a phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl ammonium and subjected to two sonication and freeze-thaw cycles. The suspensions were centrifuged at

9

10

14,000 g for 15 min at 4 °C and the supernatants were reacted with 1 mg/ml o-dianisidine hydrochloride and 0.0005% hydrogen peroxide. Optical density of each sample was read at 450 nm with a Versamax microplate reader (MDS analytical technologies). One unit of MPO activity was defined as the amount that degraded 1 μ mol peroxidase per minute at 25 °C. The results were expressed as absorbance per total quantity of proteins determined by the Bradford method.

4.8. RNA extraction and real-time qPCR

Total RNA was extracted from colonic samples with NucleoSpin RNAII kit (Macherey-Nagel). cDNA was prepared with the High Capacity cDNA Archive kit and RT-qPCR was performed with SyBrGreen (Applied Biosystems). Polymerase RNA II (PolR2A) was used as a reference gene and primer sequences are listed in Supplementary Table 1.

4.9. Statistical analysis

Significance was determined using Mann-Whitney U tests (GraphPad prism software, version 6.01).

4.10. ADME properties

ADME properties have been determined by Eurofins Panlabs (USA) as described previously [48–51].

4.11. Molecular modeling

3D homology modeling of an agonist-bound state of CB₂ receptor model has been built from CB1 crystal template with Modeller v9.20 program [52,53] has been particularly chosen in regard with the nature of its ligand (5XRA PDB entry). The initial AM11542 CB₁ agonist has been modified into the very structurally close HU210 compound, known to be also a high-affinity agonist of the CB₁/CB₂ receptors. Therefore, the ligand-biased HU210-bound 5XRA crystal template was used to build a known high-affinity agonist-bound CB₂ complex. The three critical handlings of input alignment between human CB₂ query and human CB₁ crystal sequences were (i.) the deletion of I3 intracellular loop sequence in CB₂ query without any structural template into CB₁, (*ii*.) the precision of the homologous Cys174-Cys179 disulfide bridge into CB₂ receptor, (iii.) the adjustment of sequence alignment within the E2 extracellular loop region in order to process the 2-residues deletion for the CB₂ query in respect of spatial restraints of flanking regions as well as the putative Cys174-Cys179 disulfide bridge. An energy minimization of hydrogens and side chains of the model was then performed using the CHARMM forcefield [54] and processing 5000 steps with the steepest descent algorithm converging to a 0.1 kcal mol $^{-1}$. Å $^{-1}$ gradient, followed by 20000 steps with the conjugate gradient, converging to a 0.001 kcal mol⁻¹Å⁻¹ gradient, keeping backbone quite rigid with harmonic restraints applied onto α carbons.

Docking of ligands was performed using GOLD program of GoldSuite v5.2 software [55] with a 100% automatic search into a sphere with a radius of 12 Å around the centroid of HU210 ligand. Even though 10 docking solutions were retained, early termination was allowed for three successive top-ranked poses within a RMSD of 1.5 Å.

4.12. Chemistry

Analytical thin-layer chromatography was performed on precoated Kieselgel 60F₂₅₄ plates (Merck); the spots were located by UV (254 nm). Silica gel 60 230-400 mesh purchased from Merck was used for column chromatography. Preparative thick-layer chromatography (TLC) was performed using silica gel from Merck, the compounds were eluted from the silica using EtOAc/EtOH (8:2, v/v). All melting points were determined with a Büchi 535 capillary apparatus and remained uncorrected. Nuclear magnetic resonance (¹H and ¹³C NMR) spectra were recorded at room temperature on a Bruker AC 300 spectrometer. Tetramethylsilane (TMS) was used as an internal standard and CDCl₃ or DMSO- d_6 as the solvents. ¹H NMR analyses were obtained at 300 MHz (s: singlet, d: doublet, t: triplet, g: quadruplet, quint.: quintuplet, sext.: sextuplet, hept.: heptuplet, dd: double doublet, m: multiplet); whereas ¹³C NMR analyses were obtained at 75.4 MHz. The chemical shifts (δ) are given in parts per million (ppm) relative to TMS ($\delta = 0.00$). All compounds were analyzed by LC-MS on a HPLC combined with a Surveyor MSQ (Thermo Electron) equipped with an APCI-source. All tested compounds showed purity higher than 96% in APCI⁺ mode.

6-bromobenzo[*d*]thiazol-2(3*H*)-one **27** [**3**9], 5-bromobenzo[*d*] thiazol-2(3*H*)-one **28** [**4**0], 6-bromobenzo[*d*]xazol-2(3*H*)-one **29** [**3**9] and tetrakis(triphenylphosphine)palladium [56] were prepared according to already described procedures.

4.13. General procedure for the preparation of the N-alkylated-5 or 6-bromobenzo[d]thiazol-2(3H)-one and benzo[d]xazol-2(3H)-one derivatives **30**–**36**

6-bromobenzo[*d*]thiazol-2(3*H*)-one, 6-bromobenzo[*d*]xazol-2(3*H*)-one or 5-bromobenzo[*d*]thiazol-2(3*H*)-one (10 mmol) was dissolved in 10 mL dry DMF. Cesium carbonate (20 mmol) and the corresponding haloalkane (2-bromopropyl, 1-bromobutyl, 1-bromopentyl, 1-bromohexyl, 2-dimethylaminopropyl chloride, 4-(2-chloroethyl)morpholine) (24 mmol) were added to the solution. The mixture was stirred at 80 °C overnight. The solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (50 mL) and washed with water (2 × 50 mL). The organic layer was dried over MgSO₄ and evaporated under reduced pressure.

4.14. 6-Bromo-3-pentylbenzo[d]thiazol-2(3H)-one (30)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A white powder was obtained: yield 65%; mp 47 \pm 1 °C; ¹H NMR (DMSO-*d*₆) δ 7.95 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 2.0; 8.6 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 3.90 (t, J = 7.1 Hz, 2H), 1.60 (quint., J = 6.9 Hz, 2H), 1.25 (m, 4H), 0.85 (t, J = 6.9 Hz, 3H); LC-MS (APCI⁺) *m/z* 300.0 (MH⁺).

4.15. 6-Bromo-3-isopropylbenzo[d]thiazol-2(3H)-one (31)

The product was purified by silica gel column chromatography (cyclohexane/EtOAc 8:2, v/v). A beige powder was obtained: yield 56%; mp 67 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.50 (d, J = 2.0 Hz, 1H), 7.36 (dd, J = 2.0; 8.7 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 4.75 (hept., J = 7.1 Hz, 1H), 1.54 (d, J = 7.1 Hz, 6H); LC-MS (APCI⁺) *m/z* 272.0 (MH⁺).

4.16. 6-Bromo-3-butylbenzo[d]thiazol-2(3H)-one (32)

The product was recristallized in cyclohexane. A white powder was obtained: yield 56%; mp 73 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.56 (d, J = 2.0 Hz, 1H), 7.43 (dd, J = 2.0; 8.6 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 3.93 (t, J = 7.4 Hz, 2H), 1.71 (quint., J = 7.5 Hz, 2H), 1.43 (hex., J = 7.5 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H); LC-MS (APCI⁺) *m/z* 327.0 (MH⁺ + CH₃CN).

4.17. 6-Bromo-3-hexylbenzo[d]thiazol-2(3H)-one (33)

The product was purified by silica gel column chromatography (cyclohexane/EtOAc 9:1, v/v). A beige powder was obtained: yield 66%; mp 67 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.49 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 2.0; 8.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 3.88 (t, J = 7.5 Hz, 2H), 1.68 (quint., J = 7.1 Hz, 2H), 1.29 (m, 6H), 0.85 (t, J = 6.4 Hz, 3H); LC-MS (APCl⁺) *m/z* 314.0 (MH⁺).

4.18. 6-Bromo-3-(2-dimethylaminopropyl)benzo[d]thiazol-2(3H)-one (**34**)

The product was purified by silica gel column chromatography (cyclohexane/EtOAc 9:1, v/v). A yellow oil was obtained: yield 38%; ¹H NMR (CDCl₃) δ 7.52 (d, J = 2.0 Hz, 1H), 7.39 (dd, J = 2.0; 8.6 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H), 3.97 (t, J = 7.1 Hz, 2H), 2.32 (t, J = 7.0 Hz, 2H), 2.21 (s, 6H, CH₃), 1.87 (quint., J = 7.0 Hz, 2H); LC-MS (APCI⁺) m/z 315.0 (MH⁺).

4.19. 5-Bromo-3-pentylbenzo[d]thiazol-2(3H)-one (35)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9.8:0.2, v/v). A yellow oil was obtained: yield 84%; ¹H NMR (CDCl₃) δ 7.28 (s, 1H), 7.27 (m, 1H), 7.18 (m, 1H), 3.90 (t, J = 7.4 Hz, 2H), 1.72 (m, 2H), 1.35 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H); LC-MS (APCI⁺) *m/z* 300.0 (MH⁺).

4.20. 6-Bromo-3-pentylbenzo[d]xazol-2(3H)-one (36)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9.9:0.1, v/v). A brown powder was obtained: yield 98%; mp 54 ± 1 °C; ¹H NMR (CDCl₃) δ 7.38 (d, J = 1.7 Hz, 1H), 7.32 (dd, J = 1.7; 8.3 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 3.80 (t, J = 7.3 Hz, 2H), 1.60 (m, 2H), 1.35 (m, 4H), 0.90 (t, J = 6.6 Hz, 3H); LC-MS (APCI⁺) m/z 284.0 (MH⁺).

4.21. General procedure for the preparation of the tributylstannyl intermediates **37–43**

Under nitrogen atmosphere, compounds **30–36** (3 mmol) and tetrakis(triphenylphosphine)palladium (0.3 mmol) were dissolved in 10 mL dry toluene. Hexa-*n*-butylditin (4.5 mmol) was added to the solution. The reaction was stirred at 70 °C for 20h. The solid was filtered and the filtrate evaporated under reduced pressure. The residue was washed with petroleum ether, filtered and the filtrate was evaporated under reduced pressure.

4.22. 3-Pentyl-6-(tributylstannyl)benzo[d]thiazol-2(3H)-one (37)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 95:5, v/v). A yellow oil was obtained: yield 45%; ¹H NMR (CDCl₃) δ 7.50 (s, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 3.98 (t, J = 7.5 Hz, 2H), 1.65 (m, 8H), 1.35 (m, 12H), 1.10 (m, 4H), 0.90 (m, 12H); LC-MS (APCl⁺) *m/z* 512.2 (MH⁺).

4.23. 3-Isopropyl-6-(tributylstannyl)benzo[d]thiazol-2(3H)-one (38)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 99:1, v/v). An orange oil was obtained: yield 9%; ¹H NMR (CDCl₃) δ 7.49 (s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 4.82 (hept., J = 7.1 Hz, 1H), 1.58 (d, J = 7.1 Hz, 6H), 1.56 (m, 6H), 1.35 (m, 12H), 1.08 (m, 9H); LC-MS (APCI⁺) *m/z* 484.2 (MH⁺).

4.24. 3-Butyl-6-(tributylstannyl)benzo[d]thiazol-2(3H)-one (39)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 98:2, v/v). A colorless oil was obtained: yield 36%; ¹H NMR (CDCl₃) δ 7.48 (s, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 7.8 Hz, 1H), 3.92 (t, J = 7.3 Hz, 2H), 1.65 (m, 8H), 1.37 (m, 2H), 1.35 (m, 12H), 0.89 (m, 12H); LC-MS (APCI⁺) *m/z* 498.2 (MH⁺).

4.25. 3-Hexyl-6-(tributylstannyl)benzo[d]thiazol-2(3H)-one (40)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 98:2, v/v). A colorless oil was obtained: yield 25%; ¹H NMR (CDCl₃) δ 7.44 (d, J = 0.9 Hz,1H), 7.33 (dd, J = 0.9; 7.8 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 3.87 (t, J = 7.4 Hz, 2H), 1.61 (m, 8H), 1.26 (m, 12H), 1.03 (m, 6H), 0.85 (m, 12H); LC-MS (APCI⁺) *m/z* 526.2 (MH⁺).

4.26. 3-(2-Dimethylaminopropyl)-6-(tributylstannyl)benzo[d] thiazol-2(3H)-one (**41**)

The product was purified by silica gel column chromatography (dichloromethane/MeOH 9:1, v/v). A yellow oil was obtained: yield 79%; ¹H NMR (CDCl₃) δ 7.49 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 2.0; 8.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 3.88 (t, J = 7.5 Hz, 2H), 1.68 (m, 8H), 1.29 (m, 14H), 0.85 (m, 15H); LC-MS (APCI⁺) *m/z* 526.2 (MH⁺).

4.27. 3-Pentyl-5-(tributylstannyl)benzo[d]thiazol-2(3H)-one (42)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9.6:0.4, v/v). A colorless oil was obtained: yield 52%; ¹H NMR (CDCl₃) δ 7.40 (d, J = 7.5 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.12 (s, 1H), 3.97 (t, J = 7.5 Hz, 2H), 1.75 (m, 2H), 1.60 (m, 6H), 1.35 (m, 12H), 1.12 (m, 4H), 0.90 (m, 12H); LC-MS (APCI⁺) *m*/*z* 512.2 (MH⁺).

4.28. 3-Pentyl-6-(tributylstannyl)benzo[d]xazol-2(3H)-one (43)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 96:04, v/v). A yellow oil was obtained: yield 37%; ¹H NMR (CDCl₃) δ 7.30 (s, 1H), 7.23 (d, J = 7.5 Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 3.81 (t, J = 7.4 Hz, 2H), 1.80 (m, 2H), 1.60 (m, 6H), 1.35 (m, 12H), 1.10 (m, 4H), 0.90 (m, 12H); LC-MS (APCI⁺) *m/z* 496.2 (MH⁺).

4.29. General procedure for the preparation of compounds 5–19

Under nitrogen atmosphere, a mixture of the corresponding tributyltin intermediate **37–43** (1 mmol), PdCl₂(PPh₃)₂ (0.1 mmol) and the corresponding acyl chloride (1-adamantanecarbonyl chloride, benzoyl chloride, acetyl chloride, 2,2,3,3-tetramethylcyclopropanecarbonyl chloride, cyclopentanecarbonyl chloride, cyclohexanecarbonyl chloride, cycloheptanecarbonyl chloride, (2.3 mmol) in dry toluene (4 mL) was stirred at reflux overnight. The reaction mixture was filtered and evaporated under reduced pressure.

4.30. 6-(Cyclohexanecarbonyl)-3-pentylbenzo[d]thiazol-2(3H)-one(5)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 98:2, v/v). A yellow oil was obtained: yield 26%; ¹H NMR (CDCl₃) δ 8.04 (d, J = 1.7 Hz, 1H), 7.93 (dd, J = 1.7; 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 3.95 (t, J = 7.4 Hz, 2H), 3.20 (m, 1H), 1.80 (m, 6H), 1.30 (m, 10H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 201.8 (^{IV}C), 170.0 (^{IV}C), 140.5 (^{IV}C), 131.4 (^{IV}C), 127.1 (CH), 123.2

(^{IV}C), 123.1 (CH), 110.2 (CH), 45.5 (CH₂), 43.1 (CH), 29.5 (2CH₂), 28.8 (CH₂), 27.3 (CH₂), 26.3 (CH₂), 25.9 (2CH₂), 22.3 (CH₂), 13.9 (CH₃); LC-MS (ESI) *m/z* 332.1 (MH⁺), t_r 5.06 min, λ_{max} 237 nm, purity 96.5%.

4.31. 6-Benzoyl-3-pentylbenzo[d]thiazol-2(3H)-one (6)

The product was purified by silica gel column chromatography (CH₂Cl₂/MeOH 99:1, v/v). A yellow powder was obtained: yield 89%; mp 65 ± 1 °C; ¹H NMR (CDCl₃) δ 8.13 (d, J = 1.7 Hz, 1H), 7.70 (m, 7H), 3.85 (t, J = 7.3 Hz, 2H), 1.65 (m, 2H), 1.30 (m, 4H), 0.85 (t, J = 7.0 Hz, 3H); ¹³C NMR (CDCl₃) δ 194.9 (^{IV}C), 170.0 (^{IV}C), 140.5 (^{IV}C), 137.6 (^{IV}C), 132.4 (^{IV}C), 132.4 (CH), 129.8 (2CH), 129.1 (CH), 128.4 (2CH), 125.0 (CH), 122.9 (^{IV}C), 110.0 (CH), 43.2 (CH₂), 28.9 (CH₂), 27.4 (CH₂), 22.3 (CH₂), 13.9 (CH₃); LC-MS (ESI) *m/z* 326.1 (MH⁺), t_r 4.64 min, λ_{max} 237 nm, purity 95.6%.

4.32. 3-Pentyl-6-(2,2,3,3-tetramethylcyclopropanecarbonyl)benzo [d]thiazol-2(3H)-one (7)

The product was purified by silica gel column chromatography (cyclohexane/EtOAc 9:1, v/v). A white powder was obtained: yield 50%; mp 95 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.62 (d, J = 1.8 Hz, 1H), 7.49 (dd, J = 1.8; 8.8 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 3.98 (t, J = 7.3 Hz, 2H), 1.78 (quint., J = 7.3 Hz, 2H), 1.44 (m, 1H), 1.41 (m, 4H), 1.26 (m, 6H), 1.21 (m, 6H), 0.93 (t, J = 7.0 Hz, 3H); ¹³C NMR (CDCl₃) δ 178.2 (^{IV}C), 169.9 (^{IV}C), 136.7 (^{IV}C), 135.7 (^{IV}C), 125.2 (CH), 123.9 (CH), 121.1 (^{IV}C), 111.0 (CH), 43.2 (CH₂), 35.7 (CH), 31.4 (CH₂), 29.0 (CH₂), 27.5 (2^{IV}C), 23.7 (CH₂), 22.5 (2CH₃), 16.7 (2CH₃), 14.1 (CH₃); LC-MS (APCl⁺) *m*/z 346.2 (MH⁺), t_r 5.50 min, λ_{max} 235 nm, purity 97.2%.

4.33. 6-(Cyclopentanecarbonyl)-3-pentylbenzo[d]thiazol-2(3H)-one (**8**)

The product was purified by silica gel column chromatography (cyclohexane/EtOAc 95:5, v/v). A yellow oil was obtained: yield 6%; ¹H NMR (CDCl₃) δ 8.08 (d, J = 1.7 Hz, 1H), 7.97 (dd, J = 1.7; 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 3.97 (t, J = 7.4 Hz, 2H), 3.69 (quint., J = 7.8 Hz, 1H), 1.92 (m, 4H), 1.72 (m, 6H), 1.36 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 201.0 (^{IV}C), 170.1 (^{IV}C), 140.7 (^{IV}C), 132.2 (^{IV}C), 127.4 (CH), 123.4 (CH), 123.2 (^{IV}C), 110.2 (CH), 46.3 (CH), 43.3 (CH₂), 30.2 (2CH₂), 29.0 (CH₂), 27.5 (CH₂), 26.4 (2CH₂), 22.4 (CH₂), 14.0 (CH₃); LC-MS (APCI⁺) *m/z* 318.1 (MH⁺), t_r 4.60 min, λ_{max} 245 nm, purity 98.7%.

4.34. 6-(Adamantane-1-carbonyl)-3-pentyl-benzo[d]thiazol-2(3H)-one (**9**)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc/ammoniac saturated MeOH 94:5.5:0.5, v/ v/v). A white powder was obtained: yield 68%; mp 119 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.82 (d, J = 1.3 Hz, 1H), 7.70 (dd, J = 1.3; 8.4 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 3.96 (t, J = 7.3 Hz, 2H), 2.11 (m, 3H), 2.06 (m, 6H), 1.78 (m, 6H), 1.73 (m, 2H), 1.38 (quint., J = 3.7 Hz, 4H), 0.92 (t, J = 7.2 Hz, 3H); ¹³C NMR (CDCl₃) δ 207.2 (^{IV}C), 184.4 (^{IV}C), 139.1 (^{IV}C), 133.7 (^{IV}C), 126.8 (2CH), 122.8 (^{IV}C), 109.9 (CH), 47.2 (^{IV}C), 43.2 (CH₂), 39.5 (3CH₂), 36.7 (3CH₂), 29.8 (CH₂), 29.0 (CH₂), 28.3 (3CH), 22.5 (CH₂), 14.1 (CH₃); LC-MS (ESI) *m/z* 384.2 (MH⁺), t_r 5.77 min, λ_{max} 237 nm, purity 99.6%.

4.35. 6-(1-Adamantanecarbonyl)-3-isopropylbenzo[d]thiazol-2(3H)-one (**10**)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 98:2, v/v). A white powder was obtained: yield 27%; mp 121 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.77 (d, J = 1.7 Hz, 1H),

7.67 (dd, J = 1.7; 8.6 Hz, 1H), 7.20 (d, J = 8.6 Hz, 1H), 4.82 (hept., J = 7.0 Hz, 1H), 2.09 (m, 3H), 2.04 (m, 6H), 1.90 (m, 6H), 1.57 (d, J = 7.0 Hz, 6H); 13 C NMR (CDCl₃) δ 207.1 (^{IV}C), 184.1 (^{IV}C), 169.8 (^{IV}C), 138.6 (^{IV}C), 133.2 (CH), 126.5 (CH), 122.7 (^{IV}C), 110.7 (CH), 47.1 (^{IV}C), 40.5 (CH), 39.5 (3CH₂), 36.6 (3CH₂), 28.3 (3CH), 19.5 (2CH₃); LC-MS (ESI) *m/z* 356.1 (MH⁺), t_r 4.91 min, λ_{max} 255 nm, purity 97.2%.

4.36. 6-(1-Adamantanecarbonyl)-3-butylbenzo[d]thiazol-2(3H)-one (11)

The product was purified by preparative TLC (petroleum ether/ EtOAc 99:1, v/v). A white powder was obtained: yield 17%; mp 98 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.79 (d, J = 1.7 Hz, 1H), 7.70 (dd, J = 1.7; 8.5 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 3.96 (t, J = 7.4 Hz, 2H), 2.10 (s, 3H), 2.05 (s, 6H), 1.82 (s, 6H), 1.75 (quint., J = 7.6 Hz, 2H), 1.44 (sext., J = 7.5 Hz, 2H), 0.97 (t, J = 7.1 Hz, 3H); ¹³C NMR (CDCl₃) δ 207.2 (^{IV}C), 170.0 (^{IV}C), 139.1 (^{IV}C), 133.7 (^{IV}C), 126.8 (CH), 122.8 (CH), 122.7 (^{IV}C), 109.8 (CH), 47.1 (^{IV}C), 43.0 (CH₂), 39.5 (3CH₂), 36.6 (3CH₂), 29.8 (CH₂), 28.3 (3CH), 20.2 (CH₂), 13.8 (CH₃); LC-MS (ESI) *m/z* 370.1 (MH⁺), t_r 4.99 min, λ_{max} 245 nm, purity 99.6%.

4.37. 6-(1-Adamantanecarbonyl)-3-hexylbenzo[d]thiazol-2(3H)one (**12**)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A white powder was obtained: yield 16%; mp 106 \pm 1 °C; 1 H NMR (CDCl₃) δ 7.79 (d, J = 1.5 Hz, 1H), 7.70 (dd, J = 1.5; 8.5 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 3.95 (t, J = 7.4 Hz, 2H), 2.10 (s, 3H), 2.04 (s, 6H), 1.92 (s, 6H), 1.76 (m, 2H), 1.34 (m, 6H), 0.93 (m, 3H); 13 C NMR (CDCl₃) δ 207.2 (IV C), 170.0 (IV C), 139.0 (IV C), 133.7 (IV C), 126.8 (CH), 122.7 (CH), 122.7 (IV C), 109.8 (CH), 47.1 (IV C), 43.2 (CH₂), 39.5 (3CH₂), 36.6 (3CH₂), 31.5 (CH₂), 27.9 (3CH), 27.7 (CH₂), 26.5 (CH₂), 22.6 (CH₂), 13.8 (CH₃); LC-MS (ESI) *m*/z 398.2 (MH⁺), t_r 5.78 min, λ_{max} 240 nm, purity 99.7%.

4.38. 6-(1-Adamantanecarbonyl)-3-(2-dimethylaminopropyl) benzo[d]thiazol-2(3H)-one (**13**)

The product was purified by silica gel column chromatography (dichloromethane/MeOH 9:1, v/v). A white powder was obtained: yield 25%; mp 114 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.79 (d, J = 1.5 Hz, 1H), 7.70 (dd, J = 1.5; 8.5 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 3.95 (t, J = 7.4 Hz, 2H), 2.10 (s, 3H), 2.04 (s, 6H), 1.92 (s, 6H), 1.76 (m, 2H), 1.24 (m, 5H), 0.93 (m, 3H); ¹³C NMR (CDCl₃) δ 207.2 (^{IV}C), 170.0 (^{IV}C), 139.1 (^{IV}C), 133.7 (^{IV}C), 126.8 (CH), 122.8 (CH), 122.7 (^{IV}C), 109.8 (CH), 47.1 (^{IV}C), 43.0 (CH₂), 39.5 (3CH₂), 36.6 (3CH₂), 29.8 (2CH₂), 28.3 (3CH), 20.2 (CH₃), 13.8 (CH₃); LC-MS (APCI⁺) *m/z* 399.2 (MH⁺), t_r 5.78 min, λ_{max} 235 nm, purity 99.7%.

4.39. 5-(1-Adamantanecarbonyl)-3-pentylbenzo[d]thiazol-2(3H)one (14)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A yellow oil was obtained: yield 61%; ¹H NMR (CDCl₃) δ 7.50 (dd, J = 1.4; 8.1 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.30 (s, 1H), 3.95 (t, J = 7.6 Hz, 2H), 2.05 (m, 9H), 1.75 (m, 8H), 1.35 (m, 4H), 0.90 (t, J = 7.3 Hz, 3H); ¹³C NMR (CDCl₃) δ 208.1 (^{IV}C), 183.2 (^{IV}C), 169.5 (^{IV}C), 137.1 (^{IV}C), 125.8 (^{IV}C), 122.1 (CH), 121.8 (CH), 110.0 (CH), 47.1 (^{IV}C), 43.1 (CH₂), 39.3 (3CH₂), 38.9 (CH₂), 36.5 (3CH₂), 28.9 (CH₂), 28.0 (3CH), 22.6 (CH₂), 14.0 (CH₃); LC-MS (APCI⁺) *m/z* 406.2 (M + Na), t_r 5.54 min, λ_{max} 240 nm, purity 98.2%.

4.40. 5-(Cyclohexanecarbonyl)-3-pentylbenzo[d]thiazol-2(3H)-one (15)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A yellow oil was obtained: yield 30%; ¹H NMR (CDCl₃) δ 7.74 (dd, J = 1.3; 8.2 Hz, 1H), 7.66 (d, I = 1.3 Hz, 1H), 7.52 (d, I = 8.2 Hz, 1H), 4.00 (t, J = 7.5 Hz, 2H), 3.25 (m, 1H), 1.90 (m, 4H), 1.75 (m, 2H), 1.40 (m, 10H), 0.90 (t, J = 6.8 Hz, 3H); 13 C NMR (CDCl₃) δ 202.8 (IV C), 169.4 (IV C), 137.9 (IV C), 134.7 (^{IV}C), 128.7 (^{IV}C), 123.1 (CH), 122.4 (CH), 110.0 (CH), 45.7 (CH), 43.3 (CH₂), 31.8 (CH₂), 29.6 (CH₂), 29.0 (CH₂), 27.7 (CH₂), 26.8 (CH₂), 26.0 $(2CH_2)$, 22.6 (CH_2) , 14.2 (CH_3) ; LC-MS $(APCI^+)$ m/z 354.2 (M + Na), tr 4.83 min, λ_{max} 225 nm, purity 98.5%.

4.41. 3-Pentyl-5-(2,2,3,3-tetramethylcyclopropanecarbonyl)benzo [d]thiazol-2(3H)-one (16)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A yellow powder was obtained: yield 35%; mp 61 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.55 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 1.5; 8.1 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 4.05 (t, J = 7.5 Hz, 2H), 1.80 (m, 2H), 1.30 (m, 17H), 0.88 (m, 3H); ^{13}C NMR (CDCl_3) δ 201.8 (^{IV}C), 167.8 (^{IV}C), 147.5 (^{IV}C), 135.1 (^{IV}C), 129.2 (CH), 123.0 (^{IV}C), 121.2 (CH), 104.4 (CH), 47.1 (CH₂), 34.0 (CH), 30.5 (CH₂), 30.2 (CH₂), 29.0 (2^{IV}C), 22.3 (CH₂), 21.8 (2CH₃), 17.5 (2CH₃), 13.8 (CH₃); LC-MS (APCI⁺) m/z 368.2 (M + Na), t_r 4.94 min, λ_{max} 240 nm, purity 98.9%.

4.42. 6-(1-Adamantanecarbonyl)-3-pentylbenzoldlxazol-2(3H)one (17)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A beige powder was obtained: yield 24%; mp 75 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.60 (s, 1H), 7.55 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 3.85 (t, J = 7.3 Hz, 2H), 2.10 (m, 9H), 1.75 (m, 8H), 1.35 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 207.1 (^{IV}C), 154.6 (^{IV}C), 142.1 (^{IV}C), 133.4 (^{IV}C), 133.3 (^{IV}C), 124.7 (CH), 110.0 (CH), 107.6 (CH), 47.2 (^{IV}C), 42.7 (CH₂), 39.6 (3CH₂), 36.7 (3CH₂), 31.7 (CH₂), 28.3 (3CH), 27.9 (CH₂), 22.7 (CH₂), 14.1 (CH₃); LC-MS (APCI⁺) m/z 390.2 (M + Na), t_r 5.33 min, λ_{max} 235 nm, purity 97.2%.

4.43. 6-(Cyclohexanecarbonyl)-3-pentylbenzo[d]xazol-2(3H)-one (18)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A beige powder was obtained: yield 21%; mp 65 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.88 (dd, J = 1.4; 8.2 Hz, 1H), 7.81 (d, J = 1.4 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 3.24 (m, 1H), 1.85 (m, 6H), 1.40 (m, 12H), 0.90 (t, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 202.0 (^{IV}C), 154.6 (^{IV}C), 142.8 (^{IV}C), 135.2 (^{IV}C), 131.3 (^{IV}C), 125.3 (CH), 110.0 (CH), 107.9 (CH), 45.7 (CH), 42.8 (CH₂), 31.7 (CH₂), 29.7 (CH₂), 28.9 (CH₂), 27.9 (CH₂), 26.7 (CH₂), 26.0 (2CH₂), 22.7 (CH₂), 14.1 (CH₃); LC-MS (APCI⁺) m/z 344.2 (M + Si), t_r 4.93 min, λ_{max} 246 nm, purity 97.7%.

4.44. 3-Pentyl-6-(2,2,3,3-tetramethylcyclopropanecarbonyl)benzo [*d*]*xazol-2*(3*H*)*-one* (**19**)

The product was purified by silica gel column chromatography (petroleum ether/EtOAc 9:1, v/v). A yellow oil was obtained: yield 50%; ¹H NMR (CDCl₃) δ 7.15 (m, 2H), 6.98 (d, J = 7.1 Hz, 1H), 3.85 (t, J = 7.3 Hz, 2H), 1.80 (m, 2H), 1.30 (m, 17H), 0.90 (m, 3H); LC-MS (APCI⁺) m/z 352.2 (M + Na), t_r 4.73 min, λ_{max} 235 nm, purity 96.4%.

4.45. 6-(1-Adamantylmethyl)-3-pentylbenzo[d]thiazol-2(3H)-one (**20**)

Triethylsilane (11 mmol) was added to a solution of compound 9 (5 mmol) in trifluoroacetic acid (15 mL). The reaction mixture was stirred at room temperature overnight. The solution was hydrolvzed with iced water (20 mL) and extracted with dichloromethane $(2 \times 50 \text{ mL})$. The organic layer was washed with 10% aqueous potassium carbonate (40 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by silica gel column chromatography (petroleum ether/EtOAc 98:2, v/v) and recrystallized in methanol. A white powder was obtained: yield 16%; mp $80 \pm 1 \circ C$; ¹H NMR (CDCl₃) δ 7.15 (s, 1H), 7.04 (d, J = 8.3 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 3.94 (t, J = 7.4 Hz, 2H), 2.40 (s, 2H), 1.92 (m, 5H), 1.75 (m, 2H), 1.57 (m, 5H), 1.48 (m, 5H), 1.40 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H; ¹³C NMR (CDCl₃) δ 170.0 (^{IV}C), 135.4 (^{IV}C), 133.4 (^{IV}C), 128.7 (CH), 124.3 (CH), 122.2 (^{IV}C), 109.8 (CH), 50.9 (^{IV}C), 43.0 (CH₂), 42.5 (3CH₂), 37.1 (3CH₂), 33.7 (CH₂), 29.1 (CH₂), 28.8 (3CH), 27.5 (CH₂), 22.5 (CH₂), 14.1 (CH₃); LC-MS (ESI) *m/z* 392.2 (M + Na), t_r 5.76 min, λ_{max} 338 nm, purity 97.2%.

4.46. 6-(1-Adamantylhydroxylmethyl)-3-pentylbenzo[d]thiazol-2(3H)-one (**21**)

Sodium borohydride (30 mmol) was added to a solution of compound 9 (10 mmol) in methanol (15 mL). The reaction mixture was stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure and the residue was hydrolyzed with water (20 mL). The solution was extracted with dichloromethane $(2 \times 30 \text{ mL})$, dried over MgSO₄ and evaporated under reduced pressure. The product was purified by silica gel column chromatography (petroleum ether/EtOAc 95:5, v/v) and recrystallized in acetonitrile. A grey powder was obtained: yield 26%; mp 153 ± 1 °C; ¹H NMR (CDCl₃) δ 7.36 (d, J = 1.4 Hz, 1H), 7.20 (dd, J = 1.4; 8.3 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 4.22 (s, 1H), 2.92 (t, J = 7.6 Hz, 2H), 1.98 (m, 5H), 1.90 (s, 1H), 1.70 (m, 7H), 1.50 (m, 5H), 1.35 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 170.1 (^{IV}C), 136.5 (^{IV}C), 136.3 (^{IV}C), 126.1 (CH), 122.3 (^{IV}C), 122.0 (CH), 109.6 (CH), 82.7 (CH), 43.1 (^{IV}C), 38.2 (3CH₂), 37.1 (3CH₂), 29.8 (CH₂), 29.1 (CH₂), 28.4 (3CH), 27.5 (CH₂), 22.5 (CH₂), 14.1 (CH₃); LC-MS (APCI⁺) m/z 386.2 (MH⁺), t_r 5.18 min, λ_{max} 235 nm, purity 97.8%.

4.47. 6-(1-Adamantylmethoxylmethyl)-3-pentylbenzo[d]thiazol-2(3H)-one (22)

Sodium hydride (1.67 mmol) was added to a solution of compound **21** (0.39 mmol) in THF (15 mL). Methyl iodide (1.67 mmol) was added to the solution. The reaction mixture was stirred at room temperature for 5 h. The solution was evaporated under reduced pressure and hydrolyzed with water (20 mL). The solution was extracted with dichloromethane (2×30 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by silica gel column chromatography (petroleum ether/EtOAc 95:5) and recrystallized in acetonitrile. A yellow powder was obtained: yield 39%; mp 153 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.27 (d, J = 1.4 Hz, 1H), 7.14 (dd, J = 1.4; 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 3.93 (t, J = 7.3 Hz, 2H), 3.60 (s, 1H), 3.17 (s, 3H), 1.93 (m, 3H), 1.76 (quint., J = 7.3 Hz, 2H), 1.64 (m, 10H), 1.41 (m, 6H), 0.92 (t, J = 7.1 Hz, 3H); ¹³C NMR (CDCl₃) δ 170.1 (^{IV}C), 136.5 (^{IV}C), 134.0 (^{IV}C), 126.8 (CH), 122.5 (^{IV}C), 122.3 (CH), 109.6 (CH), 92.6 (CH), 57.7 (CH₃), 43.1 (CH), 38.6 (3CH₂), 37.5 (CH₂), 37.2 (3CH₂), 29.1 (CH₂), 28.5 (3CH), 27.5 (CH₂), λ_{max} 235 nm, purity 95.3%.

22.5 (CH₂), 14.1 (CH₃); LC-MS (APCI⁺) *m/z* 399.1 (MH⁺), t_r 5.50 min,

14

4.48. 6-(1-Adamantyl-1-hydroxyiminomethyl)-3-pentylbenzo[d] thiazol-2(3H)-one (23)

Hydroxylamine hydrochloride (20 mmol) and pyridine (25 mmol) were added to a solution of compound 9 (5 mmol) in methanol (20 mL). The reaction mixture was stirred at reflux for 4 h. The solvent was evaporated under reduced pressure. The residue was hydrolyzed with water (10 mL) and the solution was acidified to pH 1 with 1N HCl solution. The solution was extracted with dichloromethane (20 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by recrystallization in absolute ethanol. White crystals were obtained: yield 25%; mp $227 \pm 1 \,^{\circ}C$; ¹H NMR (CDCl₃) δ 10.42 (s, 1H, OH), 7.33 (d, J = 8.2 Hz, 1H), 7.31 (s, 1H), 6.97 (d, J = 8.2 Hz, 1H), 3.93 (t, J = 7.1 Hz, 2H), 1.95 (m, 5H), 1.65 (m, 7H), 1.50 (m, 5H), 1.30 (m, 4H), 0.86 (t, J = 6.4 Hz, 3H); ¹³C NMR (CDCl₃) δ 169.9 (^{IV}C), 166.2 (^{IV}C), 137.0 (^{IV}C), 127.8 (^{IV}C), 126.1 (CH), 123.0 (^{IV}C), 122.0 (CH), 110.2 (CH), 43.2 (^{IV}C), 39.9 (3CH₂), 39.5 (CH₂), 36.6 (3CH₂), 29.1 (CH₂), 28.2 (3CH), 27.5 (CH₂), 22.5 (CH₂), 14.1 (CH₃); LC-MS (ESI) m/z 399.2 (MH⁺), t_r 5.14 min, λ_{max} 235 nm, purity 95.3%.

4.49. 6-(1-Adamantyl-1-methoxyiminomethyl)-3-pentylbenzo[d] thiazol-2(3H)-one (**24**)

Methoxylamine hydrochloride (20 mmol) and pyridine (25 mmol) were added to a solution of compound 9 (5 mmol) in methanol (20 mL). The reaction mixture was stirred at reflux for 4 h. The solvent was evaporated under reduced pressure. The residue was hydrolyzed with water (10 mL) and the solution was acidified to pH 1 with 1N HCl solution. The solution was extracted with dichloromethane (20 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by preparative TLC (petroleum ether/EtOAc 95:5, v/v). A white powder was obtained: yield 15%; mp 141 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.09 (d, J = 1.3 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.97 (dd, J = 1.3; 8.3 Hz, 1H), 3.94 (t, J = 7.4 Hz, 2H), 3.75 (s, 3H), 2.05 (m, 5H), 1.70 (m, 7H), 1.50 (m, 5H), 1.40 (m, 4H), 0.93 (t, $J\,{=}\,6.9\,\text{Hz},\,3\text{H});\,\,^{13}\text{C}$ NMR (CDCl_3) δ 169.9 (^{IV}C), 165.0 (^{IV}C), 136.7 (^{IV}C), 128.7 (^{IV}C), 126.0 (CH), 122.7 (^{IV}C), 121.9 (CH), 110.0 (CH), 61.8 (CH₃), 43.1 (^{IV}C), 40.2 (3CH₂), 39.2 (CH₂), 36.7 (3CH₂), 29.1 (CH₂), 28.3 (3CH), 27.5 (CH₂), 22.5 (CH₂), 14.1 (CH₃); LC-MS (ESI) m/z 413.2 (MH⁺), t_r 5.59 min, λ_{max} 250 nm, purity 98.4%.

4.50. 6-Acetylbenzo[d]thiazol-2(3H)-one (44)

Dry DMF (25 mL) was added dropwise to a flask containing aluminium chloride (80 mmol). 2,3-Dihydro-1,3-benzothiazol-2-one (10 mmol) and acetyl chloride (18 mmol) were added dropwise to the mixture. The reaction mixture was stirred at 70 °C for 5 h. The solution was hydrolyzed with iced water (10 mL) and the precipitate was filtered off, washed with water until the washing water is neutral and with absolute ethanol. The product was purified by recrystallization in absolute ethanol. A brown powder was obtained: yield 48%; mp 180 ± 1 °C; ¹H NMR (CDCl₃) δ 12.10 (s,1H, NH), 8.20 (d, J = 1.4 Hz, 1H), 7.90 (dd, J = 1.4; 8.3 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 2.60 (s, 3H); LC-MS (APCl⁺) *m/z* 194.0 (MH⁺).

4.51. 2-Oxo-2,3-dihydro-1,3-benzothiazole-6-carboxylic acid (45)

Sodium hydroxide (155 mmol) was dissolved in water (5 mL). Sodium hypochlorite (100 mL) was added to the solution and compound **44** (15 mmol) was then added dropwise. The reaction mixture was stirred at reflux for 2 h. The solution was hydrolyzed with iced water (40 mL) and acidified to pH 1 with 3N HCl solution. The precipitate was filtered off, washed with water until the washing water is neutral and washed with ethanol. The product was purified by recrystallization in ethanol. A brown powder was obtained: yield 50%; mp > 260 °C; ¹H NMR (CDCl₃) δ 12.90 (s, 1H, OH), 12.20 (s, 1H, NH), 8.15 (d, J = 1.6 Hz, 1H), 7.88 (dd, J = 1.6; 8.4 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H); LC-MS (APCI⁺) *m/z* 196.0 (MH⁺).

4.52. N-(Adamantan-1-yl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxamide (46)

HOBt (0.5 mmol), HBTU (1.5 mmol), adamantanamine hydrochloride (1.1 mmol) and DIEA (2.2 mmol) were added to a solution of compound **45** (1 mmol) in dry DMF (20 mL). The reaction mixture was stirred at room temperature under nitrogen for 18 h. The solvent was evaporated under reduced pressure. The residue was dissolved in 1N HCl (20 mL) and extracted with dichloromethane (20 mL). The organic layer was washed with 5% aqueous sodium bicarbonate (20 mL) and water (20 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by recrystallization in methanol. A yellow powder was obtained: yield 14%; mp > 260 °C; ¹H NMR (CDCl₃) δ 12.10 (s, 1H, NH), 8.15 (s, 1H, NH), 7.75 (d, J = 8.3 Hz, 1H), 7.50 (s, 1H), 7.10 (d, J = 8.3 Hz, 1H), 2.10 (m, 5H), 1.60 (m, 5H), 1.50 (m, 5H); LC-MS (APCI⁺) *m/z* 329.1 (MH⁺).

4.53. N-(Adamantan-1-yl)-2-oxo-3-pentyl-2,3-dihydrobenzo[d] thiazole-6-carboxamide (25)

Compound 46 (0.5 mmol) was dissolved in 1 mL dry DMF. Potassium carbonate (0.75 mmol) and 1-bromopentyl chloride (1.2 mmol) were added to the solution. The mixture was stirred at 80 °C overnight. The solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (10 mL) and washed with water (2×10 mL). The organic layer was dried over MgSO₄ and evaporated under reduced pressure. The product was purified by preparative TLC (cyclohexane/EtOAc 82:18, v/v). A yellow powder was obtained: yield 22%; mp 145 \pm 1 °C; ¹H NMR (CDCl₃) δ 7.82 (d, J = 1.7 Hz, 1H), 7.70 (dd, J = 1.7; 8.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 5.80 (s, 1H, NH), 3.96 (t, J = 7.5 Hz, 2H), 2.15 (m, 5H), 1.65 (m, 7H), 1.50 (m, 5H), 1.38 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H); ¹³C NMR (CDCl₃) δ 176.2 (^{IV}C), 169.7 (^{IV}C), 133.7 (^{IV}C), 133.6 (^{IV}C), 123.3 (CH), 118.7 (^{IV}C), 115.0 (CH), 110.4 (CH), 66.0 (^{IV}C), 42.9 (CH₂), 39.2 (3CH₂), 36.4 (3CH₂), 28.9 (3CH), 28.1 (CH₂), 27.3 (CH₂), 22.3 (CH₂), 13.9 (CH₃); LC-MS (ESI) m/z 399.2 (MH⁺), t_r 5.12 min, λ_{max} 260 nm, purity 99.8%.

4.54. 6-Nitrobenzo[d]thiazol-2(3H)-one (47)

Benzo[*d*]thiazol-2(3*H*)-one (10 mmol) was added to a flask containing anhydride acetic (150 mL) at 0 °C. Fuming nitric acid (30 mmol) was added dropwise at 0 °C. The precipitate was filtered off, washed with diethyl ether (50 mL) and dried. The product was purified by recrystallization in ethanol/acetonitrile (90:10, v/v). A yellow powder was obtained: yield 60%; mp 242 \pm 1 °C; ¹H NMR (CDCl₃) δ 8.37 (d, J = 2.2 Hz, 1H), 8.23 (dd, J = 2.2; 8.7 Hz, 1H), 7.30 (s, 1H, NH), 7.22 (d, J = 8.7 Hz, 1H); LC-MS (APCI⁺) *m/z* 197.0 (MH⁺).

4.55. 6-Nitro-3-pentylbenzo[d]thiazol-2(3H)-one (48)

Compound **47** (0.5 mmol) was dissolved in 1 mL dry DMF. Potassium carbonate (0.75 mmol) and 1-bromopentyl chloride (1.2 mmol) were added to the solution. The mixture was stirred at 80 °C overnight. The solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (10 mL) and washed with water (2×10 mL). The organic layer was dried over MgSO₄ and evaporated under reduced pressure. The product was purified

by silica gel column chromatography (dichloromethane/petroleum ether 50:50, v/v). A yellow powder was obtained: yield 69%; mp 55 ± 1 °C; ¹H NMR (CDCl₃) δ 8.37 (d, J = 2.3 Hz, 1H), 8.25 (dd, J = 2.3; 8.9 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 4.01 (t, J = 7.5 Hz, 2H), 1.75 (m, 2H), 1.40 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H); LC-MS (APCI⁺) *m/z* 267.1 (MH⁺).

4.56. 6-Amino-3-pentylbenzo[d]thiazol-2(3H)-one hydrochloride (49)

Palladium on carbon (catalytic amount) was added to a solution of compound **48** (4 mmol) in methanol (30 mL). The reaction mixture was stirred at room temperature under hydrogen atmosphere for 4 days. The palladium was filtered over celite and filtrate was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and saturated HCl in diethyl ether was added to the solution (10 mL). The precipitate was filtered off. The product was purified by recrystallization in acetonitrile/methanol (50:50, v/v). A silver powder was obtained: yield 57%; mp 218 \pm 1 °C; ¹H NMR (CDCl₃) δ 10.10 (s, 3H, NH³₃), 7.63 (d, J = 2.0 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 2.0; 8.6 Hz, 1H), 3.93 (t, J = 7.3 Hz, 2H), 1.65 (m, 2H), 1.30 (m, 4H), 0.84 (t, J = 6.9 Hz, 3H); LC-MS (APCl⁺) *m/z* 237.1 (MH⁺).

4.57. N-(2-oxo-3-pentyl-2,3-dihydrobenzo[d]thiazol-6-yl) adamantane-1-carboxamide (**26**)

Benzoyl chloride (1.4 mmol) was added to a solution of compound **49** (0.7 mmol) in 5% aqueous potassium carbonate/EtOAc (1:2, v/v). The reaction mixture was stirred at room temperature for 30 min. The organic layer was separated from the aqueous solution and washed with 3N HCl (10 mL), dried over MgSO₄ and evaporated under reduced pressure. The product was purified by silica gel column chromatography (dichloromethane). A yellowish powder was obtained: yield 77%; mp 115 \pm 1 °C; ¹H NMR (CDCl₃) δ 8.20 (s, 1H, NH), 7.55 (m, 7H), 7.00 (d, J = 8.7 Hz, 1H), 3.90 (t, J = 7.4 Hz, 2H), 1.70 (m, 2H), 1.35 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 170.0 (^{IV}C), 165.6 (^{IV}C), 139.4 (^{IV}C), 131.1 (^{IV}C), 125.4 (CH), 123.1 (^{IV}C), 121.6 (CH), 110.2 (CH), 52.6 (^{IV}C), 43.2 (CH₂), 41.8 (3CH₂), 36.5 (3CH₂), 29.6 (3CH), 29.0 (CH₂), 27.4 (CH₂), 22.5 (CH₂), 14.1 (CH₃); LC-MS (ESI) *m*/z 341.2 (MH⁺), t_r 5.02 min, λ_{max} 238 nm, purity 97.1%.

Acknowledgment

We are grateful for the financial support from ANR emergence (ANR-09-EBIO-007: CAB-MICI) and PRIM (Pole de Recherche Interdisciplinaire pour le Medicament).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejmech.2018.12.008.

References

- Y. Gaoni, R. Mechoulam, Isolation, structure and partial synthesis of an active constituent of Hashish, J. Am. Chem. Soc. 86 (1964) 1646–1647.
- [2] J.P. Goullé, E. Saussereau, C. Lacroix, Delta-9-tetrahydrocannabinol pharmacokinetics, Ann. Pharm. Fr. 66 (2008) 232–244.
- [3] W.P. Farquhar-Smith, Pain and cannabinoids: science and evidence, Pain Rev. 9 (2002) 41–67.
- [4] N. Leleu-Chavain, M. Body-Malapel, J. Spencer, P. Chavatte, P. Desreumaux, R. Millet, Recent advances in the development of selective CB₂ agonists as promising anti-inflammatory agents, Curr. Med. Chem. 19 (2012) 3457–3474.
- [5] D. Piomelli, The molecular logic of endocannabinoid signalling, Nat. Rev. Neurosci. 4 (2003) 873–884.
- [6] K. Mackie, Cannabinoid receptors as therapeutic targets, Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101–122.

- [7] J.A. Crippa, A.W. Zuardi, J.E. Hallak, Therapeutical use of the cannabinoids in psychiatry, Rev. Bras. Psiguiatr. 32 (2010) S56–S66.
- [8] P. Schwenkreis, M. Tegenthoff, Therapeutic use of cannabinoids in neurology, Schmerz 17 (2003) 367–373.
- [9] F.P. Lorenzo, Potential therapeutic usefulness of cannabis and cannabinoids, An. R. Acad. Nac. Med. (Madr.). 117 (2000) 595–605.
- [10] J. Singh, S. Budhiraja, Therapeutic potential of cannabinoid receptor ligands: current status, Methods Find. Exp. Clin. Pharmacol. 28 (2006) 177–183.
- [11] H. Kalant, Medicinal use of cannabis: history and current status, Pain Res. Manag. 6 (2001) 80–91.
- [12] A. Alsasua del Valle, Implication of cannabinoids in neurological diseases, Cell. Mol. Neurobiol. 26 (2006) 579–591.
- [13] N. Leleu-Chavain, P. Desreumaux, P. Chavatte, R. Millet, Therapeutical potential of CB₂ receptors in immune-related diseases, Curr. Mol. Pharmacol. 6 (2013) 183–203.
- [14] M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, E.T. Moolchan, R.A. Frank, Blockade of effects of smoked marijuana by the CB₁selective cannabinoid receptor antagonist SR141716, Arch. Gen. Psychiatr. 58 (2001) 322–328.
- [15] M. Rosenzweig, Drogues et civilisations. Une alliance ancestrale : De la guerre à la pacification, De Boeck Université, 2008.
- [16] L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, T.I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346 (1990) 561e-564e.
- [17] S. Munro, K.L. Thomas, M. Abu-Shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature 365 (1993) 61e-65e.
- [18] H. Ohta, T. Ishizaka, M. Tatsuzuki, M. Yoshinaga, I. Iida, Y. Tomishima, Y. Toda, S. Saito, N-alkylidenearylcarboxamides as new potent and selective CB₂ cannabinoid receptor agonists with good oral bioavailability, Bioorg. Med. Chem. Lett 17 (2007) 6299–6304.
- [19] J. El Bakali, G.G. Muccioli, N. Renault, D. Pradal, M. Body-Malapel, M. Djouina, L. Hamtiaux, V. Andrzejak, P. Desreumaux, P. Chavatte, et al., 4-0xo-1,4-Dihydropyridines as selective CB₂ cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series, J. Med. Chem. 53 (2010) 7918–7931.
- [20] A. Tourteau, V. Andrzejak, M. Body-Malapel, L. Lemaire, A. Lemoine, R. Mansouri, M. Djouina, N. Renault, J. El Bakali, P. Desreumaux, et al., 3-Carboxamido-5-Aryl-Isoxazoles as new CB₂ agonists for the treatment of colitis, Bioorg. Med. Chem. 21 (2013) 5383–5394.
- [21] Y. Iwata, K. Ando, K. Taniguchi, N. Koba, A. Sugiura, M. Sudo, Identification of a highly potent and selective CB₂ agonist, RQ-00202730, for the treatment of irritable bowel syndrome, Bioorg. Med. Chem. Lett 25 (2015) 236–240.
- [22] B.W. Trotter, K.K. Nanda, C.S. Burgey, C.M. Potteiger, J.Z. Deng, A.I. Green, J.C. Hartnett, N.R. Kett, Z. Wu, D.A. Henze, et al., Imidazopyridine CB₂ agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy, Bioorg. Med. Chem. Lett 21 (2011) 2354–2358.
- [23] S.P. Hollinshead, P.C. Astles, M.G. Chambers, M.P. Johnson, J. Palmer, M.W. Tidwell, Discovery and optimization of novel purines as potent and selective CB₂ agonists, Bioorg. Med. Chem. Lett 22 (2012) 4962–4966.
- [24] H.Y. Qian, Z.L. Wang, Y.L. Pan, L.L. Chen, X. Xie, J.Z. Chen, Development of quinazoline/pyrimidine-2,4(1H,3H)-diones as agonists of cannabinoid receptor type 2, ACS Med. Chem. Lett. 8 (2017) 678–681.
- [25] M.A. Tabrizi, P.G. Baraldi, P.A. Borea, K. Varani, Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2 receptor agonists, Chem. Rev. 116 (2016) 519–560.
- [26] J. Poupaert, P. Carato, E. Colacino, 2(3H)-Benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes, Curr. Med. Chem. 12 (2005) 877–885.
- [27] A.H. Abdelazeem, S.I. Khan, S.W. White, K.J. Sufka, C.R. McCurdy, Design, synthesis and biological evaluation of bivalent benzoxazolone and benzothiazolone ligands as potential anti-inflammatory/analgesic agents, Bioorg. Med. Chem. 23 (2015) 3248–3259.
- [28] D.S. Dogruer, S. Unlu, M.F. Sahin, E. Yegilada, Anti-nociceptive and antiinflammatory activity of some (2-benzoxazolone-3-yl and 2benzothiazolone-3-yl) acetic acid derivatives, II Farmaco 53 (1998) 80–84.
- [29] H. Orhan, D.S. Dogruer, B. Cakir, G. Sahin, M.F. Sahin, The *in vitro* effects of new non-steroidal anti-inflammatory compounds on antioxidant system of human erythrocytes, Exp. Toxicol. Pathol. 51 (1999) 397–402.
- [30] S. Roy, J. Gumulec, A. Kumar, M. Raudenska, M.H. Baig, H. Polanska, J. Balvan, M. Gupta, P. Babula, J. Odstrčilík, I. Choi, I. Provaznik, M. Masarik, The effect of Benzothiazolone-2 on the expression of Metallothionein-3 in modulating Alzheimer's disease, Brain Behav 7 (2017) e00799.
- [31] H. Ucar, K. Van derpoorten, S. Cacciaguerra, S. Spampinato, J.P. Stables, P. Depovere, M. Isa, B. Masereel, J. Delarge, J.H. Poupaert, Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives, J. Med. Chem. 41 (1998) 1138–1145.
- [32] T. Takashima, Y. Kadoh, S. Kumada, Pharmacological investigations of benzothiazoline derivatives, Arzneim.-Forsch. 22 (1992) 711–715.
- [33] K. Tsurumi, Y. Hiramatsu, M. Nozaki, M. Hayashi, H. Fujimura, Antiinflammatory activity of &amide hydrochloride, 4-[2-(5-chloro-2-oxo-3benzothiazolinyl)acetyl]-1-piperazine ethanol hydrochloride, Arzneim.-Forsch. 22 (1972) 716–724.
- [34] S. Yous, J.H. Poupaert, P. Chavatte, J.G. Espiard, D.H. Caignard, D. Lesieur, Synthesis and pharmacological evaluation of analgesic 6-substituted 2(3H)benzothiazolones, Drug Des. Discov. 17 (2001) 331–336.

N. Leleu-Chavain et al. / European Journal of Medicinal Chemistry xxx (xxxx) xxx

- [35] E. Stern, G.G. Muccioli, R. Millet, J.F. Goossens, A. Farce, P. Chavatte, J.H. Poupaert, D.M. Lambert, P. Depreux, J.P. Hénichart, Novel 4-oxo-1,4dihydroquinoline-3-carboxamide derivatives as new CB₂ cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling, J. Med. Chem. 49 (2006) 70–79.
- [36] E. Stern, G.G. Muccioli, B. Bosier, L. Hamtiaux, R. Millet, J.H. Poupaert, J.-P. Hénichart, P. Depreux, J.-F. Goossens, D.M. Lambert, Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB₂-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality, J. Med. Chem. 50 (2007) 5471–5484.
- [37] J. El Bakali, G.G. Muccioli, M. Body-Malapel, M. Djouina, F. Klupsch, A. Ghinet, A. Barczyk, N. Renault, P. Chavatte, P. Desreumaux, D.M. Lambert, R. Millet, Conformational restriction leading to a selective CB₂ cannabinoid receptor agonist orally active against colitis, ACS Med. Chem. Lett. 6 (2014) 198–203.
- agonist orally active against colitis, ACS Med. Chem. Lett. 6 (2014) 198–203.
 [38] P. Carato, K. Cherry, N. Lebegue, P. Berthelot, S. Yous, Synthesis of 6-cycloalkylcarbonyl-2(3*H*)-benzothiazolones via 6-tributyltin intermediates, Heterocycles 71 (2007) 2041–2047.
 [39] S. Yous, J.H. Poupaert, I. Lesieur, P. Depreux, D. Lesieur, AlCl₃-DMF reagent in
- [39] S. Yous, J.H. Poupaert, I. Lesieur, P. Depreux, D. Lesieur, AlCl₃-DMF reagent in the friedel-crafts reaction. Application to the acylation reaction of 2(3H)-Benzothiazolones, J. Org. Chem. 59 (1994) 1574–1576.
- [40] J.J. D'amico, F.G. Bollinger, J.J. Freeman, Synthesis of 2-Oxo and 2-Thioxo-3-(2H)- benzothiazoleethanimic acid anhydride with acetic acid and related products, J. Heterocycl. Chem. 25 (1988) 1503–1509.
 [41] C. Pirat, V. Ultré, N. Lebegue, P. Berthelot, S. Yous, P. Carato, New access to 5-
- [41] C. Pirat, V. Ultré, N. Lebegue, P. Berthelot, S. Yous, P. Carato, New access to 5substituted 1,3-benzothiazol-2(3H)-ones and their N-methyl analogues by a palladium coupling reaction, Synthesis (2011) 480–484.
- [42] O. Petrov, M. Gerova, K. Petrova, Y. Ivanova, New imidazole derivatives of 2(3H)-benzazolones as potential antifungal agents, J. Heterocycl. Chem. 46 (2009) 44–48.
- [43] P. Carato, S. Yous, P. Depreux, Synthesis of 6-chloromethyl benzothiazolin-2one and of 6-chloromethyl benzoxazolin-2-one, Org. Prep. Proced. Int. 32 (2000) 69–74.
- [44] G. Olah, H. Lin, J. Olah, S. Narang, Electrophilic and free radical nitration of benzene and toluene with various nitrating agents, Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 1045–1049.
- [45] S.J. Govaerts, E. Hermans, D.M. Lambert, Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors, Eur. J. Pharm. Sci. 23 (2004) 233–243.
- [46] N. Renault, X. Laurent, A. Farce, J. El Bakali, R. Mansouri, P. Gervois, R. Millet,

P. Desreumaux, C. Furman, P. Chavatte, Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features, Chem. Biol. Drug Des. 81 (2013) 442–454.

- [47] G.G. Muccioli, D. Martin, G.K. Scriba, W. Poppitz, J.H. Poupaert, J. Wouters, D.M. Lambert, Substituted 5,50-Diphenyl-2-thioxoimidazolidin-4-one as CB₁ cannabinoid receptor ligands: synthesis and pharmacological evaluation, J. Med. Chem. 48 (2005) 2509–2517.
- [48] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (1997) 3–26.
- [49] M.J. Banker, T.H. Clark, J.A. Williams, Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding, J. Pharmacol. Sci. 92 (2003) 967–974.
- [50] R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, F. MacIntyre, D.J. Rance, P. Wastall, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data, J. Pharmacol. Exp. Therapeut. 283 (1997) 46–58.
- [51] I.J. Hidalgo, T.J. Raub, R.T. Borchardt, Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology 96 (1989) 736–749.
- [52] B. Webb, A. Sali, Comparative protein structure modeling using modeller, Curr. Protoc. Bioinformatics. 54 (2016), 5.6.1-5.6.37.
- [53] T. Hua, K. Vemuri, S.P. Nikas, R.B. Laprairie, Y. Wu, L. Qu, M. Pu, A. Korde, S. Jiang, J.H. Ho, G.W. Han, K. Ding, X. Li, H. Liu, M.A. Hanson, S. Zhao, L.M. Bohn, A. Makriyannis, R.C. Stevens, Z.J. Liu, Crystal structures of agonistbound human cannabinoid receptor CB₁, Nature 547 (2017) 468–471.
- [54] B.R. Brooks, C.L. Brooks, A.D. Mackerell, L. Nilsson, R.J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S. Boresch, A. Caflisch, L. Caves, Q. Cui, A.R. Dinner, M. Feig, S. Fischer, J. Gao, M. Hodoscek, W. Im, K. Kuczera, T. Lazaridis, J. Ma, V. Ovchinnikov, E. Paci, R.W. Pastor, C.B. Post, J.Z. Pu, M. Schaefer, B. Tidor, R.M. Venable, H.L. Woodcock, X. Wu, W. Yang, D.M. York, M. Karplus, CHARMM: the biomolecular simulation program, J. Comput. Chem. 30 (2009) 1545–1614.
- [55] G. Jones, P. Willett, R.C. Glen, A.R. Leach, R. Taylor, Development and validation of a genetic algorithm for flexible docking, J. Mol. Biol. 267 (1997) 727–748.
- [56] F.A. Cotton, D.R. Coulson, L.C. Satek, S.O. Grim, Tetrakis(Triphenylphosphine) Palladium(0), Inorg. Synth. 13 (1972) 121.